Sandoz Seeks New Tariffs on Chinese Penicillin Imports
Pharmaceutical importers face potential price hikes as regulators weigh anti-dumping duties on low-cost Chinese antibiotics.
Updated on Oct. 21, 2026 in International Trade
Live Poll
Should your nation prioritize domestic medical manufacturing even if it makes essential drugs more expensive?
Sandoz has petitioned the European Commission to open an anti-dumping investigation into Chinese penicillin imports. The move aims to protect the Kundl facility in Austria, which is currently the only fully integrated penicillin plant in Europe, against cheaper foreign competition.
Why it matters
Operators in the medical and pharmaceutical sectors face mounting risks as supply dependency on China reached 86% of EU penicillin imports in 2025. This request signals a shift toward protectionist trade policy to mitigate the strategic risk of relying on a single, lower-cost market for essential medical supplies.
China's share of EU penicillin imports surged to 86% in 2025, up from 44% in 2019. Sandoz invested €200 million in its Kundl site, supported by €50 million in public funds, to bolster European production against an EU-China trade deficit of €1 billion per day.
The players
Sandoz
A major global pharmaceutical company focused on generic and biosimilar medicines, operating the last fully integrated penicillin plant in Europe.
European Commission
The executive branch of the European Union responsible for trade policy, including the authorization of anti-dumping investigations and industrial subsidies.
The details
The Sandoz factory in Kundl functions as the sole fully integrated site for penicillin production in Europe, yet it struggles to compete with Chinese antibiotics produced at significantly lower costs. By requesting an anti-dumping probe, Sandoz seeks to trigger tariff measures that could force a recalibration of import pricing. This action follows substantial public and private investment, including a €28.3 million grant from the European Commission in 2023, intended to secure domestic capacity.
Timeline
1928: Alexander Fleming discovered penicillin in London.
2019: China held a 44% share of EU penicillin imports.
2022: European amoxicillin supplies reached critical shortages.
2023: European Commission approved €28.3 million for the Kundl plant expansion.
2025: Daily EU trade deficit with China reached €1 billion.
Market Landscape
This request highlights the ongoing tension within the EU-China trade deficit, which reached €1 billion daily in 2025. It aligns with growing EU efforts to reduce reliance on foreign supply chains for essential medicine after experiencing critical shortages in 2022.
Pharmaceutical distributors and medical operators should monitor potential tariff announcements that could disrupt established import cost structures. Procurement teams must account for potential volatility in penicillin pricing and evaluate alternative, domestically sourced inventory strategies.
The takeaway
The petition underscores a wider effort to localize critical medical infrastructure against significant cost competition from Beijing. Operators should track the European Commission's response to the anti-dumping request as a signal for future import costs and regulatory scrutiny on essential medical goods.
Further reading
For broader trends in supply chain regulation, see International Trade.
Live Poll
Should your nation prioritize domestic medical manufacturing even if it makes essential drugs more expensive?
